Steven Morris, MD
Hematology & Oncology · Boca Raton, FLNPI 1033159637
Payments from drug & device makers
Across 80 payments — averaging $62.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$928
- AstraZeneca$578
- Novo Nordisk$516
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$352
- AbbVie$297
- Bayer$290
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,994100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $928 |
| AstraZeneca | 6 | $578 |
| Novo Nordisk | 6 | $516 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $352 |
| AbbVie | 5 | $297 |
| Bayer | 2 | $290 |
| Boehringer Ingelheim | 2 | $245 |
| Abbott | 2 | $208 |
| Novartis | 5 | $198 |
| Lilly USA, LLC | 4 | $179 |
| Pfizer | 5 | $147 |
| Edwards Lifesciences | 2 | $141 |
| Esperion Therapeutics, Inc. | 2 | $129 |
| Amgen | 1 | $125 |
| Sanofi | 1 | $125 |
| Boston Scientific | 1 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Medline Industries LP | 1 | $86 |
| Exact Sciences | 3 | $80 |
| Eisai Inc. | 1 | $36 |
| Nevro Corp. | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Insightec,inc | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| Urovant Sciences Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,994 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $76,622 |
| MounjaroTirzepatide | 45 | $61,110 |
| OzempicSemaglutide | 44 | $58,187 |
| XareltoRivaroxaban | 37 | $47,143 |
| TrulicityDulaglutide | 22 | $40,311 |
| TradjentaLinagliptin | 17 | $16,486 |
| FarxigaDapagliflozin Propanediol | 12 | $14,646 |
| JanuviaSitagliptin Phosphate | 19 | $12,198 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,040 |
| Atorvastatin Calcium | 348 | $3,113 |
| Levothyroxine Sodium | 287 | $2,641 |
| SynthroidLevothyroxine Sodium | 15 | $2,005 |
| Escitalopram Oxalate | 134 | $1,995 |
| Omeprazole | 136 | $1,751 |
| Metoprolol Succinate | 127 | $1,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $179 | $101,42167 claims |
| PfizerEliquis | $147 | $76,62282 claims |
| Novo NordiskOzempic | $516 | $58,18744 claims |
| Johnson & JohnsonXarelto | $928 | $47,14337 claims |
| AstraZenecaFarxiga, Symbicort | $578 | $18,68525 claims |
| Boehringer IngelheimTradjenta | $245 | $16,48617 claims |
| AbbVieSynthroid | $297 | $2,00515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Boca Raton
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.